Northern Trust Corp Raises Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Northern Trust Corp grew its stake in Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) by 1,299.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 731,742 shares of the company's stock after acquiring an additional 679,451 shares during the quarter. Northern Trust Corp owned about 0.99% of Protalix BioTherapeutics worth $1,376,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Y Intercept Hong Kong Ltd purchased a new position in Protalix BioTherapeutics during the 4th quarter worth $35,000. PFG Investments LLC purchased a new position in Protalix BioTherapeutics during the 4th quarter worth $39,000. Prudential Financial Inc. purchased a new position in Protalix BioTherapeutics during the 4th quarter worth $68,000. Marshall Wace LLP purchased a new position in Protalix BioTherapeutics during the 4th quarter worth $192,000. Finally, Renaissance Technologies LLC grew its stake in Protalix BioTherapeutics by 17.0% during the 4th quarter. Renaissance Technologies LLC now owns 1,118,000 shares of the company's stock worth $2,102,000 after buying an additional 162,100 shares during the last quarter. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. HC Wainwright boosted their target price on Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Wall Street Zen cut Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research report on Monday, May 12th.

Protalix BioTherapeutics Price Performance

PLX traded down $0.04 on Friday, reaching $1.55. 465,353 shares of the stock were exchanged, compared to its average volume of 546,382. The company's 50-day moving average price is $2.32 and its 200 day moving average price is $2.20. Protalix BioTherapeutics, Inc. has a fifty-two week low of $0.82 and a fifty-two week high of $3.10. The firm has a market capitalization of $123.39 million, a PE ratio of -11.92 and a beta of -0.05.

Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.05) earnings per share (EPS) for the quarter. Protalix BioTherapeutics had a negative net margin of 21.03% and a negative return on equity of 30.89%. As a group, equities analysts forecast that Protalix BioTherapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.